Halter G, Buck A K, Schirrmeister H, Wurziger I, Liewald F, Glatting G, Neumaier B, Sunder-Plassmann L, Reske S N, Hetzel M
Department of Thoracic and Vascular Surgery, University of Ulm, Germany.
J Thorac Cardiovasc Surg. 2004 Apr;127(4):1093-9. doi: 10.1016/j.jtcvs.2003.09.003.
2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography has been established as a standard diagnostic imaging method in the preoperative workup of suspicious pulmonary focal lesions, showing a sensitivity of more than 90% and a specificity of about 80%. Determination of malignant pulmonary lesions with FDG positron emission tomography depends on the assessment of glucose metabolism. However, false-positive findings can occur in inflammatory processes, such as sarcoidosis or pneumonia. The thymidine analogue 3-deoxy-3[(18)F]-fluorothymidine (FLT) is a new positron emission tomography tracer that more specifically targets proliferative activity of malignant lesions. The objective of this study was to determine whether FLT positron emission tomography, in comparison with FDG positron emission tomography, provides additional information in the preoperative workup of central pulmonary focal lesions.
In this prospective study FLT and FDG positron emission tomography examinations were performed as a part of the preoperative workup in 20 patients with histologically confirmed bronchial carcinoma, 7 patients with benign lesions, and 1 patient with an atypical carcinoid. Results were compared with final pathologic findings.
For staging of the primary tumor, FLT positron emission tomography revealed a sensitivity of 86% and a specificity of 100% compared with a sensitivity of 95% and a specificity of 73% for FDG positron emission tomography. For N staging, the sensitivity of FLT positron emission tomography was 57% and the specificity was 100%, and for FDG positron emission tomography, the sensitivity was 86% and the specificity was 100%, respectively.
Our preliminary findings indicate specific FLT uptake in malignant lesions. The number of false-positive findings in FDG positron emission tomography might be reduced with FLT positron emission tomography. Therefore positron emission tomography imaging with FLT represents a useful supplement to FDG in assessing the malignancy of central pulmonary focal lesions.
2-[(18)F]-氟-2-脱氧-D-葡萄糖(FDG)正电子发射断层扫描已成为可疑肺部局灶性病变术前检查的标准诊断成像方法,其灵敏度超过90%,特异性约为80%。FDG正电子发射断层扫描对恶性肺部病变的诊断取决于葡萄糖代谢的评估。然而,在炎症过程中,如结节病或肺炎,可能会出现假阳性结果。胸腺嘧啶类似物3-脱氧-3[(18)F]-氟胸腺嘧啶(FLT)是一种新的正电子发射断层扫描示踪剂,它更特异性地靶向恶性病变的增殖活性。本研究的目的是确定与FDG正电子发射断层扫描相比,FLT正电子发射断层扫描在中央型肺部局灶性病变术前检查中是否能提供更多信息。
在这项前瞻性研究中,对20例经组织学证实的支气管癌患者、7例良性病变患者和1例非典型类癌患者进行了FLT和FDG正电子发射断层扫描检查,作为术前检查的一部分。将结果与最终病理结果进行比较。
对于原发肿瘤分期,FLT正电子发射断层扫描的灵敏度为86%,特异性为100%,而FDG正电子发射断层扫描的灵敏度为95%,特异性为73%。对于N分期,FLT正电子发射断层扫描的灵敏度为57%,特异性为100%,FDG正电子发射断层扫描的灵敏度为86%,特异性为100%。
我们的初步研究结果表明恶性病变中有特异性的FLT摄取。FLT正电子发射断层扫描可能会减少FDG正电子发射断层扫描中的假阳性结果数量。因此,在评估中央型肺部局灶性病变的恶性程度时,FLT正电子发射断层扫描成像可作为FDG的有益补充。